| abstract |
A biomaterial formed from the crosslinking of at least a first and a second precursor component, in said first precursor component is selected from the group consisting of: DYC (0) - (CH2) nS- (CH2) 2-C0X-P, DYC (0) - (CH2) n-NH- (CH2) 2-C0X-P, DYC (0) - (CH2) n-NH-UP, DYC (0) - (CH2) nSUP, DYC (0) - ( CH2) nSLS-CH2-CH2-C0-XP; D-Y-C (0) - (CH2) n-S-L-U-P; D-Y-C (0) - (CH2) n-NH-L-S-CH2-CH2-C0-X-P; D-Y-C (0) - (CH2) n-NH-L-S-U-P; D-Y-C (0) - (CH2) n-S-L-NH-CH2-CH2-C0-X-P; D-Y-C (0) - (CH2) n-S-L-NH-U-P; D-Y-C (0) - (CH2) n-NH-L-NH-CH2-CH2-C0-X-P; or D-Y-C (0) - (CH2) n-NH-L-NH-U-P, where D is a pharmaceutically active branch or a link branch; n is 1, 2 or 3; Y is 0, NH or N; L is a linear or branched linker; X is 0 or N; P is a water soluble polymer or a water swellable polymer having one or more conjugated unsaturated groups; and U is the product of adding a nucleophile to an electrophilic group that is attached to the polymer. |